Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04823299

Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation

Led by Ottawa Heart Institute Research Corporation · Updated on 2026-04-29

556

Participants Needed

2

Research Sites

205 weeks

Total Duration

On this page

Sponsors

O

Ottawa Heart Institute Research Corporation

Lead Sponsor

C

Canadian Institutes of Health Research (CIHR)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Atrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effective than medications for controlling symptoms and reducing the risk of these complications; however, recurrence of AF after ablation remains a significant challenge, often due to incomplete or ineffective initial procedures. This clinical trial aims to determine whether a novel, patient-tailored ablation strategy can improve outcomes compared to the current standard-of-care approach. Participants will be randomly assigned to undergo either standard pulmonary vein isolation or a more individualized ablation procedure that identifies and targets patient-specific sources of AF. All participants will undergo the ablation procedure, receive continuous heart rhythm monitoring, and be followed over time to assess recurrence and safety outcomes.

CONDITIONS

Official Title

Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at consent
  • Diagnosed with paroxysmal atrial fibrillation with at least one documented episode in the past 12 months (patients on antiarrhythmic medications are exempt)
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Persistent or permanent atrial fibrillation
  • Prior catheter or surgical ablation for AF, atrial flutter, atrial tachycardia, AVNRT, or AVRT
  • Documented AVNRT, AVRT, atrial tachycardia, or atrial flutter before enrollment
  • Previous left atrial ablation or surgery
  • History of pulmonary vein stenosis or pulmonary vein stent
  • Pre-existing hemi-diaphragmatic paralysis
  • Active intracardiac thrombus
  • Contraindication to systemic oral anticoagulation
  • Current immunosuppressant therapy unless stopped 3 months before and after ablation
  • Reversible causes of AF such as uncontrolled hyperthyroidism or recent cardiac surgery
  • Left ventricular ejection fraction below 35%
  • NYHA Class 4 heart failure
  • Hypertrophic cardiomyopathy
  • Significant moderate or severe valve disease
  • Mechanical mitral prosthetic valves
  • Known adverse reaction to adenosine
  • Chronic kidney disease stage 4 or higher
  • Significant congenital heart disease except patent foramen ovale
  • Pregnancy
  • Stroke or transient ischemic attack within 6 months prior to consent
  • Thromboembolic events within 6 months before enrollment
  • Participation in other interventional trials affecting results
  • Primary pulmonary hypertension
  • Rheumatic heart disease
  • Thrombocytosis, thrombocytopenia, or other hypercoagulable states
  • Active systemic infection
  • Life expectancy less than 12 months
  • Inability or unwillingness to comply with study procedures and follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Ottawa Heart Institute

Ottawa, Ontario, Canada, K1Y 4W7

Actively Recruiting

2

McGill University Health Center

Montreal, Quebec, Canada, H3G 1A4

Not Yet Recruiting

Loading map...

Research Team

G

Girish Nair, MD

CONTACT

S

Sonya Jancar

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here